Alerts will be sent to your verified email
Verify Email
KABRADG
|
Kabra Drugs
|
Biofil Chem & Pharma
|
Bacil Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
36.01 % | 4.39 % | 0.32 % |
|
5yr average Equity Multiplier
|
-0.87 | 2.06 | 1.36 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 0.95 | 0.0 |
|
5yr Avg Net Profit Margin
|
0.0 | 2.38 % | 0.0 |
|
Price to Book
|
1.96 | 2.74 | 2.3 |
|
P/E
|
11.63 | 21.02 | 36.69 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 75.63 Days | 0.0 |
|
Inventory Days
|
0.0 | 28.27 Days | 0.0 |
|
Days Receivable
|
0.0 | 389.8 Days | 0.0 |
|
Days Payable
|
0.0 | 203.89 Days | 0.0 |
|
5yr Average Interest Coverage Ratio
|
-1068.45 | 23.53 | -943.72 |
|
5yr Avg ROCE
|
21.53 % | 6.37 % | -75.56 % |
|
5yr Avg Operating Profit Margin
|
0.0 | 3.78 % | 0.0 |
|
5 yr average Debt to Equity
|
-1.45 | 0.03 | 0.05 |
|
5yr CAGR Net Profit
|
43.36 % | -14.7 % | n/a |
|
5yr Average Return on Assets
|
-21.34 % | 2.37 % | -70.2 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 46.79 % | 0.0 |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -0.03 % | -42.67 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kabra Drugs
|
Biofil Chem & Pharma
|
Bacil Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|